PharmaCielo is focused on producing pharma-grade extracts.
ICANN GAP & GACP certifications allow the exportation into the Israeli market.
FACILITIES:
Over 1.3 million square feet under cultivation with open-air greenhouses.
The company is in charge of one of the world’s only advanced tissue and culture labs dedicated to in vitro propagation and long-term preservation of cannabis cultivars. This provides genetic stability, consistent crops with minimal variations, improved yield, potency and disease-resistance, pathogen-free, non-GMO and the preservation of native Colombian landrace strains which has been provided by Indigenous communities.
The company is in charge of a 2,000 sq ft state-of-the-art, GMP-certified, EU-GMP-compliant facility. The facility uses clean, natural ethanol extraction methods.
NEWS & PARTNERSHIPS:
2019
In Mexico, the company startedv a JV with MINO Labs to bring medicinal cannabis oil to Mexico.
2020
The company was declared a project of national strategic interest thanks to the company being the first licensed cannabis company in the country.
The company entered into a strategic alliance with AssuredTrans, for up-front independent laboratory analysis and insurance of its products.
The company entered the UK market with a shipment of medicinal grade CBD isolate to a well-established, bulk distributor and white label manufacturer based in the UK with sales and distribution operations in the UK and the EU for its interim sales agreement lasting until the end of 2021 with a total of 1,000 KG’s of CBD isolate and broad-spectrum CBD to be supplied.
2021
The company signed a sales agreement and completed an initial commercial sale of CBD Isolate to an undisclosed pharmaceutical company in Brazil.
2022
The company announced its first shipment of dried flower to a customer in the Czech Republic.
The company announced a sales agreement with a Brazilian phyto-therapeutic customer becoming its sole supplier of the derivative formulation which will be utilized in the production of novel herbal medicines to be distributed across Latin America.
The company signed an investment agreement with Soteria Holdings that will apply for licenses allowing the importation and wholesale of medical cannabis flower and extracts in the polish market. Soteria will also support a group of the country’s leading medical cannabis professionals to provide education and training programs to doctors in Poland allowing for the prescription prescribe of medical cannabis to their patients.
The company signed a sales agreement with Greenstein for the supply of final products containing THC and will be commercialized through NOWEDA, a pharmaceutical wholesaler to all the pharmacies in Germany. PharmaCielo will supply NOWEDA via Greenstein with 3 THC-dominant final products.
2023
The company has a strategic partnership with CANNPRISMA to supply the European Medical market with EU-GMP certified flower.
The company signed an ongoing sales agreement with Ease Labs Pharma for the companies’ API to be sold into the Brazilian Market through regular shipments.
The company announced a strategic partnership with CANNPRISMA for the supply of EU-GMP certified dried flower to CANNPRISMA which in turn will convert the flower to EU-GMP standards for distribution from Portugal to European medicinal cannabis markets.
The company announced a purchase order for CBD Isolate as an API from a large Brazilian pharmaceutical company.
The company announced a shipment of CBD Isolate for commercial testing prior to inclusion in products, to a specialty biotechnology company based in South Africa which sells in advanced medical cannabis markets globally, including the UK and Australia.
2024
The company announced a binding LOI to acquire Siam Ventures in Thailand, a company providing contract manufacturing services.
2025
The compant sold its La Margarita property in Colombia to Flores El Capiro for CAD $8.6 M. They used 2.1M CAD to pay off and negotiated down 300K CAD on its loan to Banco Agrario de Colombia.